- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05944926
Improving Outcomes in Depression in Primary Care in a Low Resource Setting (OptimizeD)
The OptimizeD study aims to improve outcomes in depression in primary care in India. This study will randomize 1500 patients with moderate to severe depression to either psychotherapy based on behavioral activation called the Healthy Activity Program (HAP) or antidepressant medication (fluoxetine).
The study has two primary objectives:
- Use patient characteristics to generate a precision treatment rule based on baseline information for predicting in advance what works best for whom (and which patients are unlikely to respond to either treatment and should be referred to specialist care).
- Conduct a cost-effectiveness analysis by comparing relative costs and effectiveness between those who were randomly allocated to their optimal treatment with those who were randomly allocated to a non-optimal treatment based on the precision treatment rule.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Depression is the leading mental health contributor to the Global Burden of Disease. The World Health Organization's mhGAP initiative advocates the use of brief psychological therapies such as behavioral activation or antidepressant medications as first-line options for the treatment of moderate to severe depression in primary care settings, but not all patients will fully remit on either treatment. It is likely that different patients will respond to different treatments, but the optimal treatment for each individual remains unknown (and which patients are unlikely to respond to either treatment and should be referred to specialist care). Enhancing our ability to determine the optimal intervention for a particular patient has the potential to enhance the overall effectiveness of mental health care delivery in a more cost-efficient manner. This is a critical gap in knowledge in the treatment of depression across clinical settings globally.
The main objective of the OptimizeD study is to determine whether different patients respond differentially to brief psychological treatment or a widely used generic SSRI and, if so, whether one can optimize outcomes in a cost-effective fashion for primary care patients with moderate to severe depression.
The study has two specific aims and two exploratory aims:
- Specific Aim 1 (Clinical and Functional Outcomes): To evaluate the effectiveness of optimization via generating a precision treatment rule (PTR) on patients with moderate to severe depression randomized to either psychotherapy based on behavioral activation called the Healthy Activity Program (HAP) or antidepressant medication (fluoxetine). The study will use machine learning to develop the PTR, using a wide range of clinical, socio-economic, and neuro-cognitive characteristics measured at baseline as predictors. The investigators hypothesize that patients randomized by chance to their optimal intervention will be more likely to remit and recover than patients who are not.
- Specific Aim 2 (Cost-effectiveness Outcomes): To assess the costs of optimal vs. non-optimal treatments and to conduct a cost-effectiveness analysis by comparing relative costs and effectiveness between those who were randomly allocated to their optimal treatment with those who were randomly allocated to a non-optimal treatment, based on the PTR developed in Aim 1. The investigators hypothesize that optimizing will be more cost-effective than not.
- Exploratory Aim 1 (Mediators): To explore whether one can use the PTR to make our tests of mediation more precise. Patients who respond differentially to different treatments adhere to different causal mechanisms, and inclusion of the PTR in interaction terms with the purported mediators should facilitate the detection of moderated mediation among patients who show specificity of response. The investigators will also consider whether treatment-related factors (e.g., adherence, quality) act as mediators of the effects of each treatment on remission and recovery. This exploratory aim will offer insights into mechanisms of action for each treatment.
- Exploratory Aim 2 (Genetic Predictors): To explore whether polygenic risk scores and other biomarkers can enhance the prediction of both general and differential response to either treatment.
As a secondary objective, the study will evaluate the effectiveness of optimization in the long-term. The investigators hypothesize that patients allocated to their optimized treatment will be more likely to recover than patients who are allocated to their non-optimal treatment.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Julia R Pozuelo, PhD
- Phone Number: 617-432-1707
- Email: julia_ruizpozuelo@hms.harvard.edu
Study Locations
-
-
Madhya Pradesh
-
Bhopal, Madhya Pradesh, India, 462016
- Recruiting
- Sangath
-
Contact:
- Deepak Tugnawat, MSW
- Phone Number: 91-8523843957
- Email: deepak.tugnawat@sangath.in
-
Principal Investigator:
- Anant Bhan, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants will be adults aged 18 or over of any gender attending one of the selected Primary Health Care Centers with a "diagnosis" of moderate to severe depression based on scores of 10 or above on the Patient Health Questionnaire-9 (PHQ-9).
Exclusion Criteria:
- Women who are pregnant or are breastfeeding or lactating
- Patients with a history of psychosis including schizophrenia spectrum disorders or bipolar disorder.
- Participants planning to move out of the study area during the follow-up period.
- Patients over 65 years of age with evidence of cognitive impairment - Patients who do not speak the study or local language (English or Hindi)
- Patients who are undergoing treatment for depression at the time of recruitment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy Activity Program (HAP)
HAP is a brief psychological treatment adapted from behavioral activation therapy, an empirically supported psychological treatment recommended by WHO.
|
HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
|
Experimental: Antidepressant medication (fluoxetine)
Fluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression.
It is a routinely used medication and part of the Essential Drug List (EDL) in India.
|
Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit.
Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression remission
Time Frame: 3 months post recruitment
|
Remission is defined as PHQ-9 total score < 5.
The PHQ-9 is a self-report measure of depressive symptoms in the prior 2 weeks.
Items are rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 27, where higher scores indicate more severe depressive symptoms.
We will dichotomised the total score using the cut-off score of 5.
|
3 months post recruitment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Generalized Anxiety Disorder Assessment (GAD-7)
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
The GAD-7 is a 7-item self-report scale to screen for symptoms of generalized anxiety disorder.
Items are rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 21, where higher scores indicate more severe anxiety symptoms.
|
3-, 6-, 9-, 12-months post recruitment
|
WHO Disability Assessment Schedule II (WHODAS-II)
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
The WHODAS-II consists of 12-items that capture level of functioning across six life domains including cognition, mobility, self-care, getting along, life activities, and participation in society.
Each item ranges from 1 (none) to 5 (extreme), with total scores from 12-60.
Raw scores are then converted to a summary score ranging from 0 (no disability) to 100 (full disability).
|
3-, 6-, 9-, 12-months post recruitment
|
Minimal Clinically Important Difference (MCID)
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
We will use the anchor-based approach for estimating MCID that ties change in outcome on the PHQ-9 to the patient's subjective sense of improvement.
We will follow Weobong (2017) methodology to compute this.
|
3-, 6-, 9-, 12-months post recruitment
|
World Health Organization Well-Being Index (WHO-5)
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
The WHO-5 consists of 5-items that measure current mental well-being.
Each item is rated on 6-point Likert scale, ranging from 0 (at no the time) to 5 (all of the time).
The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.
|
3-, 6-, 9-, 12-months post recruitment
|
Cost-effectiveness of optimization
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
Cost-effectiveness analysis by comparing costs and effectiveness between those who were randomly allocated to their optimal treatment vs. those who were randomly allocated to a non-optimal treatment.
Effectiveness will be measures by (1) likelihood of remission and (2) Quality Adjusted Life Years (QALYs).
Costs of treatments include three components: system-level costs incurred at the health facility level, individual costs incurred by HAP counselors and Medical Officers in delivering each treatment, and costs incurred by patients for participating in the treatment.
See section below for a description of these measures.
|
3-, 6-, 9-, 12-months post recruitment
|
Depression severity, as measured by the Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
The PHQ-9 is a 9-item self-report scale to screen for symptoms of depression.
Items are rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 27, where higher scores indicate more severe depressive symptoms.
|
3-, 6-, 9-, 12-months post recruitment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Client Service Receipt Inventory (CSRI)
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
Out-of-pocket costs for receiving care and the related non-medical costs.
|
3-, 6-, 9-, 12-months post recruitment
|
Quality Adjusted Life Years (QALYs) as measured by WHODAS II
Time Frame: 3-, 6-, 9-, 12-months post recruitment
|
WHODAS II is a 12-item scale that captures the level of functioning across six life domains, including cognition, mobility, self-care, getting along, life activities, and participation in society (Saltychev et al., 2021).
Each item ranges from 1 (none) to 5 (extreme), with total simple scores from 12-60.
Standardized summary scores will be converted to a preference-weighted utility index, which will then be used to compute the additional number of QALYs generated by the interventions.
The answers to two questions in WHODAS can be used to estimate the number of days in the previous month that someone was completely unable to work or able to work only part time because of a health condition.
|
3-, 6-, 9-, 12-months post recruitment
|
Recovery from depression as measured by the PHQ-9
Time Frame: 12-month post recruitment
|
Recovery from depression symptoms is defined as going nine months without relapse (PHQ-9 ≥5) following remission.
|
12-month post recruitment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Vikram Patel, MD, Vikram_Patel@hms.harvard.edu
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Selective Serotonin Reuptake Inhibitors
- Fluoxetine
- Antidepressive Agents
Other Study ID Numbers
- IRB20-2144
- 1R01MH121632-01A1 (U.S. NIH Grant/Contract)
- CTRI/2024/01/061932 (Other Identifier: Clinical Trials Registry - India (ICMR-NIMS))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Healthy Activity Program (HAP)
-
SangathHarvard Medical School (HMS and HSDM); London School of Hygiene and Tropical... and other collaboratorsRecruiting
-
Harvard Medical School (HMS and HSDM)Sangath; National Institute of Mental Health (NIMH); Massachusetts General Hospital and other collaboratorsCompleted
-
Pennington Biomedical Research CenterCompleted
-
Basque Health ServiceUnknownDigestive System Neoplasms | Breast Neoplasms | Non-Small-Cell Lung CarcinomaSpain
-
Hadassah Medical OrganizationActive, not recruitingPhysical Activity | Dietary Habits | Obesity, Childhood | Health Behavior
-
University of MiamiNational Institutes of Health (NIH); Patricia and Phillip Frost Museum of Science... and other collaboratorsCompleted
-
ElsanNot yet recruitingIndividualised Physical Activity Program | Coronary Patient
-
Universidad Santo TomasEmory University; Universidad Pública de Navarra; Universidad de Granada; University... and other collaboratorsCompletedObesity | Lipid Metabolism Disorders | Mental Health Wellness 1 | Body Composition, Beneficial | Metabolic Syndrome X
-
Northwestern UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Hillel Yaffe Medical CenterCompletedCardiovascular Diseases | AgingIsrael